Table 5.

Linear Regression Analysis for Predictors of Global Longitudinal Strain in Lymphoma Survivors

	Univariable Analysis			Multivariable Model 1 (R2 = 0.333)			Multivariable Model 2 (R2 = 0.337)
	β	95% CI	P Value	β	95% CI	P Value	β	95% CI	P Value
Male	1.29	0.21 to 2.37	0.020	1.00	0.16 to 1.99	0.046	1.02	0.03 to 2.01	0.044
Age at CMR	0.05	0.00 to 0.10	0.048	−0.04	−0.09 to 0.03	0.25	−0.04	−0.10 to 0.02	0.20
Duration between diagnosis and CMR	0.12	0.06 to 0.18	<0.001	0.10	0.02 to 0.17	0.017	0.10	0.02 to 0.18	0.014
Body mass index	0.12	−0.01 to 0.25	0.062	0.07	−0.05 to 0.20	0.24	0.07	−0.05 to 0.20	0.24
Heart rate	0.02	−0.03 to 0.07	0.38
Total mediastinal radiotherapy doses	0.07	−0.03 to 0.18	0.16	0.04	−0.05 to 0.20	0.43	0.05	−0.05 to 0.14	0.37
High-dose anthracycline–containing chemotherapy	0.59	−0.97 to 2.15	0.45
Total doses anthracycline-containing chemotherapy	0.00	−0.01 to 0.00	0.92				0.001	0.00 to 0.01	0.50
Diabetes mellitus	4.79	2.06 to 7.52	0.001	4.49	1.80 to 7.18	0.001	4.44	1.73 to 7.15	0.002
Hyperlipidemia	0.54	−1.14 to 2.23	0.52
Hypertension	0.52	−0.99 to 2.03	0.50
Hypothyroidism	0.93	−0.25 to 2.12	0.12	0.65	−0.48 to 1.78	0.25	0.64	−0.50 to 1.78	0.26
Hyperthyroidism	0.87	−2.06 to 3.80	0.56
Current or former smoker	0.73	−0.47 to 1.92	0.23

All variables with P values <0.20 in the univariable linear regression were included in multivariable model 1. In multivariable model 2, the following variables irrespective of P value were added to the model: duration between diagnosis and CMR and total dose of anthracycline-containing chemotherapy. A positive β value represents worsening of function.